Here are the top stories covered by DocWire News this week in the Hematology & Oncology section. This week, various studies from the 2019 ASH Annual Meeting focused on outcomes of chimeric antigen receptor (CAR) T-cell treatments, CVS announced it will provide genetic sequencing for some patients with cancer, and more.
CVS Health Corp said it will provide more patients with advanced cancer who are enrolled in some Aetna insurance plans the opportunity to receive broad genetic sequencing tests to help identify the most optimal treatment plan.
Long-term results from the ZUMA-1 trial presented at the 2019 ASH Annual Meeting found that three years after infusion of the CAR T-cell therapy axicabtagene ciloleucel, nearly half (n=47; 47%) of patients with refractory large B-cell lymphoma were alive.
A B-cell maturation antigen CAR T-cell therapy resulted in a 100% response rate among patients with heavily pretreated relapsed/refractory multiple myeloma, according to a study presented at the 2019 ASH Annual Meeting.
Administering a dose of the common antibiotic vancomycin before radiation therapy may help immune cells kill tumors, according to a new study published in the Journal of Clinical Investigation.
A randomized trial found no benefit of adjuvant denosumab in early breast cancer.
In case you missed it, more hem/onc headlines are featured below:
- Trastuzumab Deruxtecan Is a Potential Treatment Option for HER2+ Breast Cancer
- Breast Cancer Incidence Differs Among Black and White Males
- Experts Advise Caution when Interpreting Cancer Study Findings
- Lung Cancer Patients Taking Common Medication Often Excluded from Clinical Trials
- Two Duvelisib Doses Effective in Relapsed/Refractory Peripheral T-cell Lymphoma